Grandfather with pancreatic cancer beats the odds with clinical trial
Summary
An 83-year-old man with advanced pancreatic cancer joined a clinical trial testing a new device that delivers chemotherapy directly to the tumor. This method aims to reduce side effects and improve treatment effectiveness compared to traditional chemotherapy.Key Facts
- Hernando Salcedo was diagnosed with Stage III pancreatic cancer in May 2025.
- Traditional chemotherapy caused severe side effects, making it hard for him to eat or walk.
- A clinical trial tested RenovoRX’s RenovoCath system, which uses a catheter with balloons to deliver chemo directly to the tumor.
- This targeted delivery method reduces the amount of chemo affecting the rest of the body.
- Clinical trial data showed 65% fewer side effects and an average six-month longer survival with the catheter method.
- Salcedo received standard chemo first, then was eligible for the new catheter treatment.
- He was randomized to receive chemotherapy via the RenovoCath system and responded well, with no cancer progression after treatment cycles.
- The new treatment aims to improve life quality and survival for pancreatic cancer patients.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
